10.0 EXPERIMENTAL FACILITIES

The SHINE Medical Technologies, LLC (SHINE, the applicant) final safety analysis report (FSAR) chapter 10, “Experimental Facilities,” states that the SHINE facility does not contain experimental facilities as described in NUREG-1537, Part 1, “Guidelines for Preparing and Reviewing Applications for the Licensing of Non-Power Reactors, Format and Content,” issued February 1996 and the “Final Interim Staff Guidance Augmenting NUREG-1537, Part 1, ‘Guidelines for Preparing and Reviewing Applications for the Licensing of Non-Power Reactors: Format and Content,’ for Licensing Radioisotope Production Facilities and Aqueous Homogeneous Reactors,” dated October 17, 2012.

The U.S. Nuclear Regulatory Commission staff evaluated the descriptions and discussions of the SHINE facility in the FSAR and finds that the final design of the SHINE facility does not contain experimental facilities. Therefore, the staff concluded that an evaluation of the guidelines of NUREG-1537, Part 2, “Guidelines for Preparing and Reviewing Applications for the Licensing of Non-Power Reactors, Standard Review Plan and Acceptance Criteria,” issued February 1996 and the “Final Interim Staff Guidance Augmenting NUREG-1537, Part 2, ‘Guidelines for Preparing and Reviewing Applications for the Licensing of Non-Power Reactors: Standard Review Plan and Acceptance Criteria,’ for Licensing Radioisotope Production Facilities and Aqueous Homogeneous Reactors,” dated October 17, 2012, is not required.